9,10-dimethyl-1,2-benzanthracene has been researched along with losartan in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, AM; Alorro, M; Chand, AL; Clyne, CD; Connelly, AA; Coulson, R; Deb, S; Ernst, M; George, AJ; Hannan, NJ; Harrison, CA; Kumar, B; Lazarus, KA; Liew, SH; Morrow, RJ; O'Toole, SA; Parslow, AC; Poh, A; Putoczki, T; Vargas, AC; Walton, KL; Yeap, EFW; Yee, NS | 1 |
1 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and losartan
| Article | Year |
|---|---|
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiotensin II Type 1 Receptor Blockers; Animals; Biopsy; Breast Neoplasms; Carcinogenesis; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Disease Progression; Female; Humans; Immunohistochemistry; Interleukin-6; Losartan; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Mice; Neoplasm Invasiveness; Phosphorylation; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Tumor Necrosis Factor-alpha; Up-Regulation | 2017 |